VALERIO THERAPEUTICS ANNOUNCES CHANGES IN THE COMPOSITION OF ITS BOARD OF DIRECTORS
Paris (France), November 26, 2025
Valerio Therapeutics S.A. (“Valerio Therapeutics” or the “Company”) (Euronext Growth Paris: ALVIO) announces the co-optation of Dr. Antonin (Tony) de Fougerolles, Ph. D, to the Board of Directors of the Company, effective immediately.
Dr. Antonin (Tony) de Fougerolles previously served as the founding Chief Scientific Officer of Moderna, Chief Scientific Officer of Ablynx, VP Research at Alnylam, and more recently as Chief Executive Officer of Evox Therapeutics. Over the course of his nearly 30-year career in drug development, he has played a key role in the creation of three transformative therapeutic platforms (mRNA, RNAi, single domain antibodies (sdAbs)) and has built out drug pipelines that have resulted in the approval of numerous medicines in areas such as infectious diseases, cardiology, and rare diseases.
Dr. Antonin (Tony) de Fougerolles brings extensive expertise and knowledge of RNAs and sdAbs, gained and recognized at Ablynx, Alnylam and Moderna. He has also contributed to the growth of several start-ups that have subsequently become multibillion-dollar companies. Dr. Antonin de Fougerolles will thus contribute to the Company’s operational development and advise the Company on fundraising matters and the selection of the most suitable therapeutic indications.
Dr. Antonin (Tony) de Fougerolles said: « I am very impressed with the integrated expertise the Valerio team has in both the RNA and sdAbs fields which enables them to rapidly develop differentiated drugs through the combination of these two drug platforms. I look forward to working alongside the Valerio Therapeutics management team and Board of Directors as the company continues to advance toward key milestones ».
Julien Miara, Chief Executive Officer of Valerio Therapeutics, added: «We are pleased to welcome Antonin to the Board of Directors. We believe that his perspective and extensive experience in immunology and oncology will be undeniable in supporting the evolution of Valerio Therapeutics and will save us valuable time in the development of drug candidates ».
For more information, visit www.valeriotx.com.
CONTACTS
Valerio Therapeutics
Investor Relations:
ir@valeriotx.com | +33 (0) 1 45 58 95 10
********************************
Forward-Looking Statements
This press release contains express or implied forward-looking statements relating to Valerio Therapeutics and its business. These statements depend on known and unknown risks, uncertainties and other factors that could cause Valerio Therapeutics’ actual results, financial conditions, performance or achievements to differ materially from any results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Valerio Therapeutics issues this press release as of this date and does not undertake any obligation to update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of the risks and uncertainties that could cause Valerio Therapeutics’ actual results, financial conditions, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors described in the Company’s annual financial report or other periodic financial report or press release available free of charge on the Company’s website (www.valeriotx.com) and/or the AMF website (www.amf-france.org).
